



Margaritis Avgeris

Assoc. Professor - School of Medicine

National and Kapodistrian University of Athens (NKUA)

e-mail: mavgeris@med.uoa.gr ; margaritis.avgeris@gmail.com

Current Position

Associate Professor, School of Medicine, National and Kapodistrian University of Athens, Greece (2020-today)

- Laboratory of Clinical Biochemistry – Molecular Diagnostics**, 2nd Dept. of Pediatrics, “P. & A. Kyriakou” Children’s Hospital, School of Medicine, NKUA
- Department of Biochemistry and Molecular Biology**, Faculty of Biology, NKUA (*Affiliated Member*)

Education

PostDoc Research Fellow, Dept. of Biochemistry and Molecular Biology, Faculty of Biology, NKUA (2015-19)

Ph.D. Thesis, Dept. of Biochemistry and Molecular Biology, Faculty of Biology, NKUA (2010-15),

M.Sc. (Master) in “Clinical Biochemistry & Molecular Diagnostics”, NKUA (2005-2007).

B.Sc. Biology, Faculty of Biology, NKUA (1999-2004).

Research Interests

- Cancer Research – RNA biology
- Molecular Diagnostics – Molecular cancer biomarkers
- Non-coding RNAs – miRNAs, lncRNAs, tRFs
- Epigenetics (DNA methylation)
- Cell-free DNA (cfDNA) – Liquid biopsies
- Epitranscriptomics (RNA methylation)
- Next Generation Sequencing (NGS)

Links

PubMed: <https://pubmed.ncbi.nlm.nih.gov/?term=Avgeris+M&sort=date>

Google Scholar: <https://scholar.google.com/citations?user=v6yBiJ4AAAAJ&hl=en&oi=ao>

UoA Scholar: <http://scholar.uoa.gr/mavgeris>

Orcid: <https://orcid.org/0000-0002-2135-9886>

LinkedIn: <https://www.linkedin.com/in/margaritis-avgeris-a4659b8b/?originalSubdoma...>

Patents

- Scorilas A, **Avgeris M**, Thomaidis NS, Voulgaris N, Adamopoulos PG. Detection and mutational analysis of an RNA virus in an environmental sample. (Intern. Pub. No. WO2022171313A1, Intern. Applic. No. PCT/EP2021/057316 – filing date: 22-03-2021)
- Σκορίλας Α, **Αυγέρης Μ**, Θωμαΐδης Ν, Βούλγαρης Ν, Αδαμόπουλος ΠΓ. Ανίχνευση και ανάλυση μεταλλάξεων RNA ιών σε περιβαλλοντικά δείγματα. (ΟΒΙ Αριθ. Διπλ. Ευρεσ.: 1010565, Αριθ. Αίτησης Διπλ. Ευρεσ. #20210100091/11-02-2021.
- Scorilas A, **Avgeris M**, Thomaidis NS, Voulgaris N, Adamopoulos PG. Mutational detection and screening of RNA virus using nested amplification and targeted next generation sequencing in low concentration samples. (OBI Application No. 2412-0004687111- filing date: 06-04-2023).

Associate Editor

Journal of Translational Medicine

Referee for international scientific Journals:

Clinical Chemistry, Clinical Cancer Research, JCO Precision Oncology, Cancer, Cancer Gene Therapy, Carcinogenesis, Cancer Epidemiol, Biomark & Prevent, Cancers, DNA and Cell Biology, Molecular & Cellular Biochemistry, Int J Mol Sci, Clinical Biochemistry, Cancer Management and Research, Expert Review of Molecular Diagnosis, Molecular Diagnosis and Therapy, Frontiers in Oncology, BMC Cancer, Tumor Biology, Scientific Reports, BioMed Research International, Disease Markers, Int J Clin Med, Thrombosis and Haemostasis, J Proteom & Bioinformatics, Acta Diabetologica, Hormones, Journal of Clinical Virology, PeeJ, The Pharmacogenomics Journal

Publications in International, Peer-Reviewed Scientific Journals

[PubMed](#) listed publications in international peer-reviewed scientific journals, including:

Nature Medicine, Annals of Oncology, Clinical Cancer Research, Trends Mol Med, Molecular Therapy, Molecular Therapy Nucleic Acids, Clinical Chemistry, EMBO Reports, Br J Cancer, Eur J Cancer, WIREs RNA, Trends Anal Chem, Sci Total Environ, etc.

1. Pilala KM, Panoutsopoulou K, Papadimitriou MA, Soureas K, Scorilas A, **Avgeris M**. Exploring methyl-verse: dynamic interplay of epigenome and m6A epitranscriptome. ***Molecular Therapy*** 2025; 33(2):447-464. DOI: [10.1016/j.ymthe.2024.12.003](https://doi.org/10.1016/j.ymthe.2024.12.003) (IF₂₀₂₄=12.1)
2. Soureas K, Malandrakis P, Papadimitriou MA, Minopoulos C, Ntanasis-Stathopoulos I, Liacos CI, Gavriatopoulou M, Kastiris E, Dimopoulos MA, Scorilas A, **Avgeris M***, Terpos E*. Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome. ***Blood Cancer Journal*** 2025; 15(1):41. DOI: [10.1038/s41408-025-01248-2](https://doi.org/10.1038/s41408-025-01248-2) (IF₂₀₂₄=12.9) *Equal last authors
3. Karaviti D, Charakida M, Dimopoulou D, Marmarinos A, Papadaki M, Maritsi D, Spyridis N, **Avgeris M**, Gourgiotis D, Tsolia M. Long-term Effects of SARS-CoV-2 Infection on Children's Vasculature. ***Pediatr Infect Dis J***. 2025. DOI: [10.1097/INF.0000000000004786](https://doi.org/10.1097/INF.0000000000004786) (IF₂₀₂₄=2.9)
4. Damianaki A, Marmarinos A, **Avgeris M**, Gourgiotis D, Vlachopapadopoulou EA, Charakida M, Tsolia M, Kossiva L. Lifestyle and Biochemical Parameters That May Hamper Immune Responses in Pediatric Patients After Immunization with the BNT162b2 mRNA COVID-19 Vaccine. ***Diseases*** 2025; 13(3):78. DOI: [10.3390/diseases1303007](https://doi.org/10.3390/diseases1303007) (IF₂₀₂₄=2.9).
5. Papadimitriou MA, Pilala KM, Panoutsopoulou K, Levis P, Kotronopoulos G, Kanaki Z, Loules G, Zamanakou M, Linardoutsos D, Sideris DC, Stravodimos K, Klinakis A, Scorilas A, **Avgeris M**. *CDKN2A* copy number alteration in bladder cancer: integrative analysis in patient-derived xenografts and cancer patients. ***Molecular Therapy Oncology*** 2024; 32(2):200818. DOI: [10.1016/j.omton.2024.200818](https://doi.org/10.1016/j.omton.2024.200818) (IF₂₀₂₄=5.3)
6. Papailiou S, Soldatou A, Marmarinos A, **Avgeris M**, Papathoma E, Sindos M, Georgantzi S, Rodolakis A, Iacovidou N, Gourgiotis D, Tsolia M. Seroprevalence of diphtheria, tetanus and pertussis antibodies and Tdap vaccination in pregnant women in Greece – A cross-sectional study. ***Vaccine*** 2024; 42(26):126435. DOI: [10.1016/j.vaccine.2024.126435](https://doi.org/10.1016/j.vaccine.2024.126435) (IF₂₀₂₄=4.5)
7. Soureas K, Papadimitriou MA, Malandrakis P, Papanota AM, Adamopoulos PG, Ntanasis-Stathopoulos I, Liacos CI, Gavriatopoulou M, Sideris DC, Kastiris E, Dimopoulos MA, Scorilas A, Terpos E, **Avgeris M**. Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: Loss of mitochondrial i-tRF^{HisG} results in patients' poor treatment outcome. ***British Journal of Haematology*** 2024; 204(5):1790-1800. DOI: [10.1111/bjh.19332](https://doi.org/10.1111/bjh.19332) (IF₂₀₂₄=5.1)
8. Pilala KM, Kotronopoulos G, Levis P, Giagkos GC, Stravodimos K, Vassilacopoulou D, Scorilas A, **Avgeris M**. *MIR145* core promoter methylation in pre-treatment cell-free DNA: a liquid biopsy tool for muscle-invasive bladder cancer treatment outcome. ***JCO Precision Oncology*** 2024; 8:e2300414. DOI: [10.1200/PO.23.00414](https://doi.org/10.1200/PO.23.00414). (IF₂₀₂₄=5.3)
9. Adamopoulos PG, Diamantopoulos MA, Boti MA, Zafeiriadou A, Galani A, Kostakis M, Markou A, Sideris DC, **Avgeris M**, Thomaidis NS, Scorilas A. Spike-Seq: An amplicon-based high-throughput sequencing approach for the sensitive detection and characterization of SARS-CoV-2 genetic variations in environmental samples. ***Sci Total Environ***. 2024; 914:169747. DOI: [10.1016/j.scitotenv.2023.169747](https://doi.org/10.1016/j.scitotenv.2023.169747) (IF₂₀₂₄=8.2)
10. Dimopoulou D, Charakida M, Marmarinos A, Karaviti D, **Avgeris M**, Gourgiotis D, Tsolia MN. SARS-CoV-2 Antibody Kinetics in Unvaccinated Hospitalized Children With COVID-19. ***Pediatr Infect Dis J*** 2024; 43(6):536-542. DOI: [10.1097/INF.0000000000004301](https://doi.org/10.1097/INF.0000000000004301) (IF₂₀₂₄=2.9)
11. Soureas K, Papadimitriou MA, Panoutsopoulou K, Pilala KM, Scorilas A, **Avgeris M**. Cancer Quiescence: non-coding RNAs in the spotlight. ***Trends in Molecular Medicine*** 2023, 29(10):843-858. DOI: [10.1016/j.molmed.2023.07.003](https://doi.org/10.1016/j.molmed.2023.07.003) (IF₂₀₂₄=12.8)
12. Papadimitriou MA, Levis P, Kotronopoulos G, Stravodimos K, **Avgeris M***, Scorilas A*. Pre-operative cell-free DNA (cfDNA) in muscle-invasive bladder cancer treatment outcome. ***Clinical Chemistry*** 2023, 69(4):399-410. DOI: [10.1093/clinchem/hvac218](https://doi.org/10.1093/clinchem/hvac218) (IF₂₀₂₄=7.1) *Equal last authors

13. Panoutsopoulou K, Magkou P, Dreyer T, Dorn J, Obermayr E, Mahner S, Gorp VT, Braicu I, Magdolen V, Zeillinger R, **Avgeris M***, Scorilas A*. tRNA-derived small RNA 3'U-tRF^{ValC} promotes tumor migration and early-progression in ovarian cancer. *European Journal of Cancer* 2023, 180:134-145. DOI: [10.1016/j.ejca.2022.11.033](https://doi.org/10.1016/j.ejca.2022.11.033) (IF₂₀₂₄=7.6)
*Equal last authors
14. Pilala KM, Papadimitriou MA, Panoutsopoulou K, Barbarigos P, Levis P, Kotronopoulos G, Stravodimos K, Scorilas A, **Avgeris M**. Epigenetic regulation of MIR145 core promoter controls miR-143/145 cluster in bladder cancer progression and treatment outcome. *Molecular Therapy Nucleic Acids* 2022, 30:311-322. DOI: [10.1016/j.omtn.2022.10.001](https://doi.org/10.1016/j.omtn.2022.10.001) (IF₂₀₂₄=6.5)
15. Diamantopoulos MA, Georgoulia KK, Levis P, Kotronopoulos G, Stravodimos K, Kontos CK, **Avgeris M**, Scorilas A. 28S rRNA-Derived Fragments Represent an Independent Molecular Predictor of Short-Term Relapse in Prostate Cancer. *Int J Mol Sci* 2023;25(1):239. DOI: [10.3390/ijms25010239](https://doi.org/10.3390/ijms25010239) (IF₂₀₂₄=4.9)
16. Pagoni M, Cava C, Sideris DC, **Avgeris M**, Zoumpourlis V, Michalopoulos I, Drakoulis N. miRNA-Based Technologies in Cancer Therapy. *Journal of Personalized Medicine* 2023;13(11):1586. DOI: [10.3390/jpm13111586](https://doi.org/10.3390/jpm13111586) (IF₂₀₂₄=3.0)
17. Liu Y, Gong W, Panoutsopoulou K, Singer-Cornelius T, Augustin K, Bronger H, Kiechle M, Dorn J, Scorilas A, **Avgeris M**, Magdolen V, Dreyer T. Association of high miR-27a, miR-206, and miR-214 expression with poor patient prognosis and increased chemoresistance in triple-negative breast cancer. *Am J Cancer Res* 2023, 13(6):2471-2487. PMID: [37424802](https://pubmed.ncbi.nlm.nih.gov/37424802/) (IF₂₀₂₄=3.6).
18. Papasavva M, Amvrosiou S, Pilala KM, Soureas K, Christodoulou P, Ji Y, Stravodimos K, Xu D, Scorilas A, **Avgeris M**, Christodoulou MI. Deregulated Expression of IL-37 in Patients with Bladder Urothelial Cancer: The Diagnostic Potential of the IL-37e Isoform. *Int J Mol Sci* 2023, 24(11):9258. DOI: [10.3390/ijms24119258](https://doi.org/10.3390/ijms24119258) (IF₂₀₂₄=4.9).
19. Papadimitriou MA, Soureas K, Papanota AM, Tsiakanikas P, Adamopoulos PG, Ntanas-Stathopoulos I, Malandrakis P, Gavriatopoulou M, Sideris DC, Kastiris E, **Avgeris M**, Dimopoulos MA, Terpos E, Scorilas A. miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma. *Journal of Translational Medicine* 2023, 21(1):245. DOI: [10.1186/s12967-023-04034-5](https://doi.org/10.1186/s12967-023-04034-5) (IF₂₀₂₄=6.1).
20. Pateras IS*, Williams C*, Gianniou DD*, Margetis AT*, **Avgeris M***, Rousakis P, Legaki AI, Mirtschink P, Zhang W, Panoutsopoulou K, Delis AD, Pagakis SN, Tang W, Ambs S, Warpman Berglund U, Helleday T, Varvarigou A, Chatzigeorgiou A, Nordström A, Tsitsilonis OE, Trougakos IP, Gilthorpe JD, Frisan T. Short term starvation potentiates the efficacy of chemotherapy in triple negative breast cancer via metabolic reprogramming. *Journal of Translational Medicine* 2023, 21(1):169. DOI: [10.1186/s12967-023-03935-9](https://doi.org/10.1186/s12967-023-03935-9) (IF₂₀₂₄=6.1). *Equal first authors.
21. Gianniou DD, Sklirou AD, Papadimitriou MA, Pilala KM, Stravodimos K, **Avgeris M**, Scorilas A, Trougakos IP. Evaluation of the Small Heat Shock Protein Family Members HSPB2 and HSPB3 in Bladder Cancer Prognosis and Progression. *Int J Mol Sci*. 2023, 24(3):2609. DOI: [10.3390/ijms24032609](https://doi.org/10.3390/ijms24032609) (IF₂₀₂₄=4.9).
22. Martzoukou O, Amillis A, Glekas P, Breyanni D, **Avgeris M**, Scorilas A, Kekos D, Pachnos M, Mavridis G, Mamma D, Hatzinikolaou D. Advancing desulfurization in the model biocatalyst *Rhodococcus qingshengii* IGTS8 via an *in locus* combinatorial approach. *Appl Environ Microbiol* 2023, 28;89(2):e0197022. DOI: [10.1128/aem.01970-22](https://doi.org/10.1128/aem.01970-22) (IF₂₀₂₄=3.9)
23. Panoutsopoulou K, Liu Y, **Avgeris M**, Dreyer T, Dorn J, Magdolen V, Scorilas A. Repression of miR-146a in predicting poor treatment outcome in triple-negative breast cancer. *Clin Biochem*. 2023, 114:43-51. DOI: [10.1016/j.clinbiochem.2022.12.004](https://doi.org/10.1016/j.clinbiochem.2022.12.004) (IF₂₀₂₄=2.5)
24. Mavreli D, Theodora M, Lambrou G, **Avgeris M**, Papantoniou N, Treager-Synodinos J, Daskalakis G, Kolialexi A. First trimester maternal plasma proteomic changes predictive of spontaneous moderate/late preterm delivery. *J Matern Fetal Neonatal Med* 2023, 36(2):2232074. DOI: [10.1080/14767058.2023.2232074](https://doi.org/10.1080/14767058.2023.2232074) (IF₂₀₂₄=1.7)
25. Galani A, Markou A, Dimitrakopoulos L, Kontou A, Kostakis M, Kapes V, Diamantopoulos MA, Adamopoulos PG, **Avgeris M**, Lianidou E, Scorilas A, Paraskevis D, Tsiodras S, Dimopoulos MA, Thomaidis N. Delta SARS-CoV-2 variant is entirely substituted by the omicron variant during the fifth COVID-19 wave in Attica region. *Sci Total Environ* 2023, 856(Pt 1):159062. DOI: [10.1016/j.scitotenv.2022.159062](https://doi.org/10.1016/j.scitotenv.2022.159062) (IF₂₀₂₄=8.2)
26. Mavreli D, Theodora M, **Avgeris M**, Papantoniou N, Antsaklis P, Daskalakis G, Kolialexi A. First Trimester Maternal Plasma Aberrant miRNA Expression Associated with Spontaneous Preterm Birth. *Int J Mol Sci*. 2022, 23(23):14972. DOI: [10.3390/ijms232314972](https://doi.org/10.3390/ijms232314972) (IF₂₀₂₄=4.9)
27. Martzoukou O, Glekas PD, **Avgeris M**, Mamma D, Scorilas A, Kekos D, Amillis S, Hatzinikolaou DG. Interplay between Sulfur Assimilation and Bidesulfurization Activity in *Rhodococcus qingshengii* IGTS8: Insights into a

Regulatory Role of the Reverse Transsulfuration Pathway. *mBio* 2022, e0075422. DOI: [10.1128/mbio.00754-22](https://doi.org/10.1128/mbio.00754-22) (IF₂₀₂₄=5.1)

28. Papadimitriou MA, Panoutsopoulou K, Pilala KM, Scorilas A, **Avgeris M**. Epi-miRNAs: modern mediators of methylation status in human cancers. *WIREs RNA* 2022, e1735. DOI: [10.1002/wrna.1735](https://doi.org/10.1002/wrna.1735) (IF₂₀₂₄=6.4)
29. Papailiou S, Soldatou A, Marmarinos A, **Avgeris M**, Papathoma E, Sindos M, Georgantzi S, Rodolakis A, Iacovidou N, Gourgiotis D, Tsoia M. Inadequate protection against measles and rubella among pregnant women in Greece during the last measles outbreak. *Journal of Infection* 2022, S0163-4453(22)00194-3. DOI: [10.1016/j.jinf.2022.04.012](https://doi.org/10.1016/j.jinf.2022.04.012) (IF₂₀₂₄=14.3)
30. Papadimitriou MA, Papanota AM, Adamopoulos PG, Pilala KM, Liacos CI, Malandrakis P, Mavrianou-Koutsoukou N, Patseas D, Eleutherakis-Papaiaikovou E, Gavriatopoulou M, Kastiris E, **Avgeris M**, Dimopoulos MA, Terpos E, Scorilas A. miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. *British Journal of Cancer* 2022, 126(1):79-90. DOI: [10.1038/s41416-021-01602-8](https://doi.org/10.1038/s41416-021-01602-8) (IF₂₀₂₄=6.4)
31. Galani A, Aalizadeh R, Kostakis M, Markou A, Alygizakis N, Lytras T, Adamopoulos PG, Peccia J, Thompson DC, Kontou A, Karagiannidis A, Lianidou ES, **Avgeris M**, Paraskevis D, Tsiodras S, Scorilas A, Vasiliou V, Dimopoulos MA, Thomaidis NS. SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions. *Sci Total Environ.* 2022, 804:150151. DOI: [10.1016/j.scitotenv.2021.150151](https://doi.org/10.1016/j.scitotenv.2021.150151) (IF₂₀₂₄=8.2).
32. Panoutsopoulou K, Dreyer T, Dorn J, Obermayr E, Mahner S, Gorp TV, Braicu I, Zeillinger R, Magdolen V, **Avgeris M**, Scorilas A. tRNA^{GlyGCC}-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression. *Cancers* 2021, 14(1):24. DOI: [10.3390/cancers14010024](https://doi.org/10.3390/cancers14010024) (IF₂₀₂₄=4.5)
33. Xagorari M, Marmarinos A, Kossiva L, Baka M, Doganis D, Servtzooglou M, Tsoia M, Scorilas A, **Avgeris M**, Gourgiotis D. Overexpression of the GR Riborepressor LncRNA GAS5 Results in Poor Treatment Response and Early Relapse in Childhood B-ALL. *Cancers* 2021, 13(23):6064. DOI: [10.3390/cancers13236064](https://doi.org/10.3390/cancers13236064) (IF₂₀₂₄=4.5)
34. Papanota AM, Karousi P, Kontos CK, Artemaki PI, Liacos CI, Papadimitriou MA, Bagratuni T, Eleutherakis-Papaiaikovou E, Malandrakis P, Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastiris E, **Avgeris M**, Dimopoulos MA, Scorilas A, Terpos E. A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. *Int J Mol Sci.* 2021, 22(23):13144. DOI: [10.3390/ijms222313144](https://doi.org/10.3390/ijms222313144) (IF₂₀₂₄=4.9)
35. **Avgeris M**, Adamopoulos PG, Galani A, Xagorari M, Gourgiotis D, Trougakos IP, Voulgaris N, Dimopoulos MA, Thomaidis NS, Scorilas A. Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater. *Int J Mol Sci.* 2021, 22(16):8498. DOI: [10.3390/ijms22168498](https://doi.org/10.3390/ijms22168498) (IF₂₀₂₄=4.9)
36. Papanota AM, Tsiakanikas P, Kontos CK, Malandrakis P, Liacos CI, Ntanasis-Stathopoulos I, Kanellias N, Gavriatopoulou M, Kastiris E, **Avgeris M**, Dimopoulos MA, Scorilas A, Terpos E. A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. *Cancers* 2021, 13(15):3877. DOI: [10.3390/cancers13153877](https://doi.org/10.3390/cancers13153877) (IF₂₀₂₄=4.5)
37. Kanaki Z, Voutsina A, Markou A, Pateras IS, Potaris K, **Avgeris M**, Makrythanasis P, Athanasiadis EI, Vamvakaris I, Patsea E, Vachlas K, Lianidou E, Georgoulas V, Kotsakis A, Klinakis A. Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity. *Cancers* 2021, 13(10):2446. DOI: [10.3390/cancers13102446](https://doi.org/10.3390/cancers13102446) (IF₂₀₂₄=4.5).
38. Pateras IS, Kotsakis A, **Avgeris M**, Baliou E, Kouroupakis P, Patsea E, Georgoulas V, Menez-Jamet J, Kinet JP, Kosmatopoulos K. Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in “Immune Desert” NSCLC. *Cancers* 2021, 13(7):1658. DOI: [10.3390/cancers13071658](https://doi.org/10.3390/cancers13071658) (IF₂₀₂₄=4.5)
39. **Avgeris M**, Marmarinos A, Gourgiotis D, Scorilas A. Jagged Ends of Cell-Free DNA: Rebranding Fragmentomics in Modern Liquid Biopsy Diagnostics. *Clinical Chemistry* 2021, 67(4):576–578. DOI: [10.1093/clinchem/hvab036](https://doi.org/10.1093/clinchem/hvab036) (IF₂₀₂₄=7.1)
40. Tokas T, **Avgeris M**, Leotsakos I, Nagele U, Gözen AS. Impact of three-dimensional vision in laparoscopic partial nephrectomy for renal tumors; A comparison with conventional laparoscopy. *Turk J Urol* 2021, 47(2):144-150. DOI: [10.5152/tud.2020.20439](https://doi.org/10.5152/tud.2020.20439) (IF₂₀₂₄=1.0)
41. Papadimitriou MA, **Avgeris M**, Levis P, Papasotiriou EC, Kotronopoulos G, Stravodimos K, Scorilas A. tRNA-derived fragments (tRFs) in bladder cancer: Increased 5'-tRF-LysCTT results in disease early-progression and patients' poor treatment outcome. *Cancers* 2020, 12(12):3661. DOI: [10.3390/cancers12123661](https://doi.org/10.3390/cancers12123661) (IF₂₀₂₄=4.5)

42. Alygizakis N, Markou AN, Rousis NI, Galani A, **Avgeris M**, Adamopoulos PG, Scorilas A, Lianidou ES, Paraskevis D, Tsiodras S, Tsakris A, Dimopoulos MA, Thomaidis NS. Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives. *Trends in Analytical Chemistry* 2021, 134:116125. DOI: [10.1016/j.trac.2020.116125](https://doi.org/10.1016/j.trac.2020.116125) (IF₂₀₂₄=11.8)
43. Panoutsopoulou K, **Avgeris M**, Magkou P, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Loverix L, Braicu I, Sehoul J, Zeillinger R, Magdolen V, Scorilas A. miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients. *International Journal of Cancer* 2020, 147(12):3560-3573. DOI: [10.1002/ijc.33182](https://doi.org/10.1002/ijc.33182) (IF₂₀₂₄=5.7)
44. **Avgeris M**, Kokkinopoulou I, Maratou E, Mitrou P, Boutati E, Scorilas A, Fragoulis EG, Christodoulou MI. Blood-based analysis of 84 microRNAs identifies specific molecules with deregulated expression in patients and individuals at risk for type-2 diabetes. *Diabetes Res Clin Pract* 2020, 164:108187. DOI: [10.1016/j.diabres.2020.108187](https://doi.org/10.1016/j.diabres.2020.108187) (IF₂₀₂₄=6.1)
45. Leontariti M, **Avgeris M**, Katsarou MS, Drakoulis N, Siatouni A, Verentzioti A, Alexoudi A, Fytraki A, Patrikelis P, Vassilacopoulou D, Gatzonis S, Sideris DC. Circulating miR-146a and miR-134 in predicting drug resistant focal impaired awareness epilepsy. *Epilepsia* 2020, 61(5):959-970. DOI: [10.1111/epi.16502](https://doi.org/10.1111/epi.16502) (IF₂₀₂₄=6.6).
46. Minoudi S, Karaïskou N, **Avgeris M**, Gkagkavouzis K, Tarantili P, Triantafyllidou D, Palilis L, Avramopoulou V, Tsikliras A, Barmperis K, Triantafyllidis A. Seafood mislabeling in Greek markets using DNA barcoding analyses. *Food Control* 2020, 113:107213. DOI: [10.1016/j.foodcont.2020.107213](https://doi.org/10.1016/j.foodcont.2020.107213) (IF₂₀₂₄=5.6)
47. Papadimitriou MA, **Avgeris M**, Levis PK, Tokas T, Stravodimos K, Scorilas A. ΔNp63 transcript underexpression in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression. *J Cancer Res Clin Oncol* 2019, 145(12):3075-3087. DOI: [10.1007/s00432-019-03028-5](https://doi.org/10.1007/s00432-019-03028-5) (IF₂₀₂₄=2.7).
48. **Avgeris M**, Panoutsopoulou K, Papadimitriou MA, Scorilas A. Circulating exosomal miRNAs: clinical significance in human cancers. *Expert Review of Molecular Diagnostics*. 2019, 19(11):979-995. DOI: [10.1080/14737159.2019.1673732](https://doi.org/10.1080/14737159.2019.1673732) (IF₂₀₂₄=3.9).
49. Panoutsopoulou K, **Avgeris M**, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Vanderstichele A, Braicu I, Sehoul J, Zeillinger R, Magdolen V, Scorilas A. miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. *Carcinogenesis* 2020, 41(4):442-451. DOI: [10.1093/carcin/bgz163](https://doi.org/10.1093/carcin/bgz163) (IF₂₀₂₄=3.3)
50. Economopoulou P, Koutsodontis G, **Avgeris M**, Strati A, Kroupis C, Pateras I, Kirodimos E, Giotakis E, Kotsantis I, Maragoudakis P, Gorgoulis V, Scorilas A, Lianidou E, Psyrris A. HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: a pilot study. *PLoS One* 2019, 14(5):e0215984. DOI: [10.1371/journal.pone.0215984](https://doi.org/10.1371/journal.pone.0215984) (IF₂₀₂₄=2.9)
51. Giannopoulou AF, Velentzas A, Konstantakou E, **Avgeris M**, Katarachia S, Papandreou N, Kalavros N, Mpakou V, Iconomidou V, Anastasiadou E, Kostakis I, Papassideri I, Voutsinas G, Scorilas A, Stravopodis DJ. Revisiting histone deacetylases in human tumorigenesis: the paradigm of urothelial bladder cancer. *Int J Mol Sci* 2019, 20(6):1291. DOI: [10.3390/ijms20061291](https://doi.org/10.3390/ijms20061291) (IF₂₀₂₄=4.9)
52. **Avgeris M**, Tsilimantou A, Levis PK, Rampias T, Papadimitriou MA, Panoutsopoulou K, Stravodimos K, Scorilas A. Unravelling UCA1 lncRNA prognostic utility in urothelial bladder carcinoma. *Carcinogenesis* 2019 Aug 22;40(8):965-974. DOI: [10.1093/carcin/bgz045](https://doi.org/10.1093/carcin/bgz045) (IF₂₀₂₄=3.3)
53. Giannopoulou AF, Konstantakou EG, Velentzas AD, Avgeris SN, **Avgeris M**, Papandreou NC, Zoi I, Filippa V, Katarachia S, Lampidonis AD, Prombona A, Syntichaki P, Piperi C, Basdra EK, Iconomidou V, Papadavid E, Anastasiadou E, Papassideri IS, Papavassiliou AG, Voutsinas GE, Scorilas A, Stravopodis DJ. Gene-specific intron retention serves as molecular signature that distinguishes melanoma from non-melanoma cancer cells in Greek patients. *Int J Mol Sci*. 2019, 20(4):937. DOI: [10.3390/ijms20040937](https://doi.org/10.3390/ijms20040937) (IF₂₀₂₄=4.9)
54. Christodoulou MI, **Avgeris M***, Kokkinopoulou I*, Maratou E, Mitrou P, Kontos CK, Pappas E, Boutati E, Scorilas A, Fragoulis E. Blood-based analysis of type-2 diabetes mellitus susceptibility genes identifies specific transcript variants with deregulated expression and association with disease risk. *Sci Rep* 2019, 9(1):1512. DOI: [10.1038/s41598-018-37856-1](https://doi.org/10.1038/s41598-018-37856-1) (IF₂₀₂₄=3.8)
55. Rampias T, Karagiannis D, **Avgeris M**, Polyzos A, Kokkalis A, Kanaki Z, Kousidou E, Tzetis M, Kanavakis E, Stravodimos K, Manola KN, Pantelias GE, Scorilas A, Klinakis A. The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer. *EMBO Reports* 2019, 20(3):e46821. DOI: [10.15252/embr.201846821](https://doi.org/10.15252/embr.201846821) (IF₂₀₂₄=6.5)

56. Kontos CK, **Avgeris M**, Vassilacopoulou D, Ardavanis A, Scorilas A. Molecular effects of treatment of human colorectal cancer cells with natural and classical chemotherapeutic drugs: alterations in the expression of apoptosis-related BCL2 family members, including *BCL2L12*. *Curr Pharm Biotechnol* 2018, 19(13):1064-1075. DOI: [10.2174/1389201019666181112101410](https://doi.org/10.2174/1389201019666181112101410) (IF₂₀₂₄=2.2)
57. **Avgeris M**, Tsilimantou A, Levis PK, Tokas T, Sideris DC, Stravodimos K, Ardavanis A, Scorilas A. Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients. *British Journal of Cancer* 2018, 119(12):1477-1486. DOI: [10.1038/s41416-018-0320-6](https://doi.org/10.1038/s41416-018-0320-6) (IF₂₀₂₄=6.4)
58. Panoutsopoulou K, **Avgeris M**, Scorilas A. miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers. *Expert Review of Molecular Diagnostics* 2018, 18(11):963-979. DOI: [10.1080/14737159.2018.1538794](https://doi.org/10.1080/14737159.2018.1538794) (IF₂₀₂₄=3.9)
59. **Avgeris M**, Stamati L, Kontos CK, Piatopoulou D, Marmarinos A, Xagorari M, Baka M, Doganis D, Anastasiou T, Kosmidis H, Gourgiotis D, Scorilas A. *BCL2L12* improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia. *Clinical Chemistry and Laboratory Medicine* 2018, 56(12):2104-2118. DOI: [10.1515/cclm-2018-0507](https://doi.org/10.1515/cclm-2018-0507) (IF₂₀₂₄=3.8)
60. Piatopoulou D, **Avgeris M**, Drakaki I, Marmarinos A, Xagorari M, Baka M, Pourtsidis A, Kossiva L, Gourgiotis D, Scorilas A. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia. *Annals of Hematology* 2018, 97(7):1169-1182. DOI: [10.1007/s00277-018-3292-y](https://doi.org/10.1007/s00277-018-3292-y) (IF₂₀₂₄=3.0)
61. Tsikrika FD, **Avgeris M**, Levis PK, Tokas T, Stravodimos K, Scorilas A. miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression. *Genes Chromosomes & Cancer* 2018, 57(3):150-161. DOI: [10.1002/gcc.22516](https://doi.org/10.1002/gcc.22516) (IF₂₀₂₄=3.1)
62. Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, Economopoulou P, Kotsantis I, **Avgeris M**, Mazel M, Perisanidis C, Sasaki C, Alix-Panabières C, Lianidou E, Psyrri A. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. *Annals of Oncology* 2017, 28(8):1923-1933. DOI: [10.1093/annonc/mdx206](https://doi.org/10.1093/annonc/mdx206) (IF₂₀₂₄=56.7).
63. Piatopoulou D, **Avgeris M**, Marmarinos A, Xagorari M, Baka M, Doganis D, Kossiva L, Scorilas A, Gourgiotis D. miR-125b predicts childhood acute lymphoblastic leukemia poor response to BFM chemotherapy treatment. *British Journal of Cancer* 2017, 117(6):801-812. DOI: [10.1038/bjc.2017.256](https://doi.org/10.1038/bjc.2017.256) (IF₂₀₂₄=6.4)
64. Tokas T, Gözen AS, **Avgeris M**, Tschada A, Fiedler M, Klein J, Rassweiler J. Combining of ETHOS operating ergonomic platform, 3D laparoscopic camera, and Radius Surgical System Manipulators improves ergonomics in urologic laparoscopy: comparison with conventional laparoscopy and da Vinci in a pelvi trainer. *European Urology Focus* 2017 Oct;3(4-5):413-420. DOI: [10.1016/j.euf.2016.11.006](https://doi.org/10.1016/j.euf.2016.11.006) (IF₂₀₂₃=4.8)
65. Psyrri A, Fortpied C, Koutsodontis G, **Avgeris M**, Kroupis C, Goutas N, Menis J, Herman L, Giurgea L, Remenar E, Degardin M, Pateras IS, Langendijk JA, van Herpen C, Awada A, Germà-Lluch JR, Kienzer HR, Licitra L, Vermorken JB. Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: A subset analysis of EORTC 24971 study. *Annals of Oncology* 2017, 28(9):2213-2218. DOI: [10.1093/annonc/mdx320](https://doi.org/10.1093/annonc/mdx320) (IF₂₀₂₄=56.7).
66. Kontos CK, Tsiakanikas P, **Avgeris M**, Papadopoulos IN, Scorilas A. miR-15a-5p, a novel prognostic biomarker, predicting recurrent colorectal adenocarcinoma. *Molecular Diagnosis and Therapy* 2017 Aug; 21(4):453-464. DOI: [10.1007/s40291-017-0270-3](https://doi.org/10.1007/s40291-017-0270-3) (IF₂₀₂₄=4.1)
67. Tokas T, **Avgeris M**, Alamanis C, Scorilas A, Stravodimos K, Constandinidis C. Downregulated *KLK13* expression in bladder cancer highlights tumor aggressiveness and unfavourable patients' prognosis. *J Cancer Res Clin Oncol* 2017, 143(3):521-532. DOI: [10.1007/s00432-016-2301-6](https://doi.org/10.1007/s00432-016-2301-6) (IF₂₀₂₄=2.7)
68. **Avgeris M** and Scorilas A. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: Focus on prostate cancer and skin pathologies. *Expert Opinion on Therapeutic Targets* 2016, 20(7):801-18. DOI: [10.1517/14728222.2016.1147560](https://doi.org/10.1517/14728222.2016.1147560) (IF₂₀₂₄=4.6)
69. Vassilakopoulou M*, **Avgeris M***, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK, Giotakis AI, Scorilas A, Rimm L, Sasaki CT, Fountzilias G, Psyrri A. Evaluation of PD-L1 expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. *Clinical Cancer Research* 2016, 22(3):704-13. DOI: [10.1158/1078-0432.CCR-15-1543](https://doi.org/10.1158/1078-0432.CCR-15-1543) (IF₂₀₂₂=10.0) *Equal first author

70. Stamati L, **Avgeris M**, Kosmidis H, Baka M, Anastasiou T, Piatopoulou D, Scorilas A, Gourgiotis D. Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse. *J Cancer Res Clin Oncol* 2015, 141(11):2023-36. DOI: [10.1007/s00432-015-1982-6](https://doi.org/10.1007/s00432-015-1982-6) (IF₂₀₂₄=2.7)
71. **Avgeris M**, Mavridis K, Tokas T, Stravodimos K, Fragoulis EG, Scorilas A. Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. *Carcinogenesis* 2015, 36(5):528-37. DOI: [10.1093/carcin/bgv024](https://doi.org/10.1093/carcin/bgv024) (IF₂₀₂₄=3.3)
72. Rampias T, Vgenopoulou P, **Avgeris M**, Polyzos A, Stravodimos K, Valavanis C, Scorilas A, Klinakis A. A new tumor suppressor role for the Notch pathway in bladder cancer. *Nature Medicine* 2014, 20(10):1199-205. DOI: [10.1038/nm.3678](https://doi.org/10.1038/nm.3678) (IF₂₀₂₄=58.7)
73. **Avgeris M**, Stravodimos K, Scorilas A. Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients. *Biol Chem* 2014, 395(9):1095-104. DOI: [10.1515/hsz-2014-0150](https://doi.org/10.1515/hsz-2014-0150) (IF₂₀₂₄=2.9)
74. Mavridis K, **Avgeris M**, Scorilas A. Targeting kallikrein-related peptidases in prostate cancer. *Expert Opinion on Therapeutic Targets* 2014, 18(4):365-83. DOI: [10.1517/14728222.2014.880693](https://doi.org/10.1517/14728222.2014.880693) (IF₂₀₂₄=4.6)
75. Foutadakis S, **Avgeris M**, Tokas T, Stravodimos K, Scorilas A. Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors. *Urologic Oncology* 2014, 32(1):39.e29-36. DOI: [10.1016/j.urolonc.2013.04.005](https://doi.org/10.1016/j.urolonc.2013.04.005) (IF₂₀₂₄=2.9)
76. **Avgeris M**, Stravodimos K, Fragoulis EG., Scorilas A. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. *British Journal of Cancer* 2013, 108(12):2573-81. DOI: [10.1038/bjc.2013.250](https://doi.org/10.1038/bjc.2013.250) (IF₂₀₂₄=6.4)
77. Koutalellis G, Stravodimos K, **Avgeris M**, Mavridis K, Scorilas A, Lazaris A, Constantinides C. L-DOPA Decarboxylase (DDC) gene expression is related to prostate cancer patients' outcome. *BJU International* 2012, 110 (6PtB): E267-73. DOI: [10.1111/j.1464-410X.2012.11152.x](https://doi.org/10.1111/j.1464-410X.2012.11152.x) (IF₂₀₂₄=3.7).
78. **Avgeris M**, Mavridis K, Scorilas A. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. *Biol Chem* 2012, 393(5):301-17. DOI: [10.1515/hsz-2011-0260](https://doi.org/10.1515/hsz-2011-0260) (IF₂₀₂₄=2.9)
79. **Avgeris M**, Papachristopoulou G, Polychronis A, Scorilas A. Down-regulation of Kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast tumors. *Clin Proteom* 2011, 8(1):5. DOI: [10.1186/1559-0275-8-5](https://doi.org/10.1186/1559-0275-8-5) (IF₂₀₂₄=2.8)
80. **Avgeris M**, Stravodimos K, Scorilas A. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance. *Prostate* 2011, 71(16):1780-9. DOI: [10.1002/pros.21395](https://doi.org/10.1002/pros.21395) (IF₂₀₂₄=2.6)
81. Papachristopoulou G, **Avgeris M**, Charlaftis A, Scorilas A. Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues. *Thrombosis and Haemostasis* 2011; 105(1):131-7. DOI: [10.1160/TH10-02-0092](https://doi.org/10.1160/TH10-02-0092) (IF₂₀₂₄=5.0)
82. **Avgeris M**, Mavridis K, Scorilas A. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. *Biol Chem* 2010, 391(5):505-11. DOI: [10.1515/BC.2010.056](https://doi.org/10.1515/BC.2010.056) (IF₂₀₂₄=2.9)
83. Mavridis K, **Avgeris M**, Koutalellis G, Stravodimos K, Scorilas A. Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia. *Cancer Science* 2010; 101(3):693-9. DOI: [10.1111/j.1349-7006.2009.01450.x](https://doi.org/10.1111/j.1349-7006.2009.01450.x) (IF₂₀₂₄=4.5)
84. Papachristopoulou G, **Avgeris M**, Scorilas A. Expression analysis and study of KLK4 in benign and malignant breast tumors. *Thrombosis and Haemostasis* 2009; 101(2):381-7. DOI: [10.1160/TH08-01-0037](https://doi.org/10.1160/TH08-01-0037) (IF₂₀₂₄=5.0)
85. **Avgeris M**, Koutalellis G, Fragoulis EG., Scorilas A. Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer. *Clin Biochem* 2008, 41(14-15):1140-9. DOI: [10.1016/j.clinbiochem.2008.04.026](https://doi.org/10.1016/j.clinbiochem.2008.04.026) (IF₂₀₂₄=2.5)